It has been suggested to me that I reconsider an orchiectomy (versus first-line ADT) after opting for degarelix, then lupron for the last few years. Of course the decision depends in part on my own situation, but I am asking for opinions as to the following:
–might an orchiectomy preclude participation in some clinical trials?
–I am not aware of any RCTs, but as best I can discern from the literature (see sample below) the side effects of an orchiectomy, though slightly different, are similar enough to the side effects of injections that they can be disregarded for someone in good health.
–Any other external factors to consider (yes, I know, an orchiectomy rules out iADT)?
I have read, and appreciated, “Surgical Castration. Why is it uncommon?” pjoshea13
and also a retrospective study:
prostatecancerinfolink.net/...]
All 3,295 patients included had a primary diagnosis of metastatic prostate cancer (i.e., these were not men whose cancer was diagnosed at an earlier stage and then progressed over time).
Compared to patients treated with LHRH agonists, the patients treated by surgical orchiectomy had
Lower risk for bone fractures (hazard ratio [HR] = 0.77; P =0.01)
Lower risk for peripheral arterial disease (HR = 0.65; P=0.004)
Lower risk for cardiac-related complications (HR = 0.74; P =0.01)
Similar risk for diabetes
Similar risk for cognitive disorders
Thanks,